ERBB2 and breast carcinoma: Racial disparities are particularly pronounced in estrogen receptor-positive/ERBB2-negative (ER + /HER2-) breast cancer, where Black patients treated with adjuvant chemotherapy experience worse outcomes than their White counterparts, a pattern that is less evident in ER- disease3,4,6–8.